Efficacy and safety of CD19 CAR T constructed with a new anti-CD19 chimeric antigen receptor in relapsed or refractory acute lymphoblastic leukemia.

Gu R, Liu F, Zou D, Xu Y, Lu Y, Liu B, Liu W, Chen X, Liu K, Guo Y, Gong X, Lv R, Chen X, Zhou C, Zhong M, Wang H, Wei H, Mi Y, Qiu L, Lv L, Wang M, Wang Y, Zhu X, Wang J

Open source

DOI: 10.1186/s13045-020-00953-8
Published: 2020 Sep 7
Container: Journal of hematology & oncology
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1186/s13045-020-00953-8,
  title = {Efficacy and safety of CD19 CAR T constructed with a new anti-CD19 chimeric antigen receptor in relapsed or refractory acute lymphoblastic leukemia.},
  author = {Gu R and Liu F and Zou D and Xu Y and Lu Y and Liu B and Liu W and Chen X and Liu K and Guo Y and Gong X and Lv R and Chen X and Zhou C and Zhong M and Wang H and Wei H and Mi Y and Qiu L and Lv L and Wang M and Wang Y and Zhu X and Wang J},
  year = {2020},
  journal = {Journal of hematology \& oncology},
  doi = {10.1186/s13045-020-00953-8},
  url = {https://doi.org/10.1186/s13045-020-00953-8}
}

RIS

TY  - JOUR
TI  - Efficacy and safety of CD19 CAR T constructed with a new anti-CD19 chimeric antigen receptor in relapsed or refractory acute lymphoblastic leukemia.
AU  - Gu R
AU  - Liu F
AU  - Zou D
AU  - Xu Y
AU  - Lu Y
AU  - Liu B
AU  - Liu W
AU  - Chen X
AU  - Liu K
AU  - Guo Y
AU  - Gong X
AU  - Lv R
AU  - Chen X
AU  - Zhou C
AU  - Zhong M
AU  - Wang H
AU  - Wei H
AU  - Mi Y
AU  - Qiu L
AU  - Lv L
AU  - Wang M
AU  - Wang Y
AU  - Zhu X
AU  - Wang J
PY  - 2020
JO  - Journal of hematology & oncology
DO  - 10.1186/s13045-020-00953-8
UR  - https://doi.org/10.1186/s13045-020-00953-8
ER  -

APA

R, G., F, L., D, Z., Y, X., Y, L., B, L., W, L., X, C., K, L., Y, G., X, G., R, L., X, C., C, Z., M, Z., H, W., H, W., Y, M., L, Q., L, L., M, W., Y, W., X, Z., & J, W. (2020). Efficacy and safety of CD19 CAR T constructed with a new anti-CD19 chimeric antigen receptor in relapsed or refractory acute lymphoblastic leukemia.. Journal of hematology & oncology. https://doi.org/10.1186/s13045-020-00953-8

Source records

pubmed · retrieved 2026-09-26T12:58:37.554Z